shares of Outlook Therapeutics Inc (OTLK) on
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Cranbury, New Jersey and currently employs 14 full-time employees. The firm is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. The company is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The firm offers BioSymphony Platform. The firm has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The firm has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The firm’s other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab.